Clinical trial · Interventional
Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women
Implication of Combined Adjuvant Metformin and Aromatase Inhibitor in Overweight or Obese Postmenopausal Breast Cancer Women
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Metformin is an anti-diabetic oral hypoglycemic agent that considered the gold standard therapy for the treatment of type 2 diabetes. Retrospective analyses show that metformin can offer therapeutic benefits to patients with several forms of cancer. It also has positive weight reducing effect on non-diabetic patient by improving insulin sensitivity (although the exact underlying pathomechanisms remain to be elucidated).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Metformin | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- NO_INTERVENTION
- label
- Control group
- description
- fifteen obese females who received letrozole only
- type
- ACTIVE_COMPARATOR
- label
- metformin group
- description
- fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily
- interventionNames
- Drug: Metformin
- type
- NO_INTERVENTION
- label
- lean group
- description
- fifteen non- obese breast cancer females who received letozole for six months, treatment period
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal women, postmenopausal is defined either by: A. Age ≥ 55 years and one year or more of amenorrhea. B. Age \< 55 years and one year or more of amenorrhea, with an estradiol assay \< 20 pg/ml. • Patients with breast cancer indicated for hormonal treatment with aromatase inhibitors (overweight 30 \> BMI ≥ 25, obese BMI ≥ 30 kg/m2 and non obese BMI between 18 and 25 kg/m2). Exclusion Criteria: * • Diabetic patients. * Patients with metabolic syndrome. * Patients with last menstrual cycle less than one year ago. * Patient with conditions predispose to acidosis (heart failure, renal failure). * Ovarian radiation treatment with luteinizing hormone-releasing hormone (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression.
References
Publications (1)
- DERIVEDEl-Attar AA, Ibrahim OM, Alhassanin SA, Essa ES, Mostafa TM. Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. Eur J Clin Pharmacol. 2023 Feb;79(2):299-309. doi: 10.1007/s00228-022-03444-6. Epub 2022 Dec 23. PMID 36562831